Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  108.00 0.97% 11,258.00 11,276.00 11,278.00 11,350.00 11,222.00 11,240.00 1,578,494 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27,668.9 -196.0 5.9 1,707.1 174,399

Astrazeneca Share Discussion Threads

Showing 5726 to 5748 of 5825 messages
Chat Pages: 233  232  231  230  229  228  227  226  225  224  223  222  Older
Oh Dear – Peer Reviewed Journal Published Study
– mRNA VAXX – The Immune System >>>> Does Not React ... Anything Like A Real Covid Infection

- It Destroys Beneficials & Amplifies The Detrimental .

The many alterations in the vaccine mRNA …...hide the mRNA….. from cellular defenses …..and promote a longer biological half-life >>>> and high production of spike protein.

However, the….. immune response>>>>> to the vaccine
>>>> is very different >>>> from that to a SARS-CoV-2 infection.

In this paper, we explore the scientific literature suggesting that vaccination with an mRNA vaccine >>>> initiates a set of biological events
- that are not only different ….. from that induced by infection
>>>> but are in several ways …...demonstrably
>>>> counterproductive to both short >>>> and long-term …..immune competence
>>> and normal cellular function.

In this paper, we present evidence >>>> that vaccination induces ……
- a profound impairment in type I interferon signaling,
- which has diverse >>>> adverse consequences to human health.

Immune cells that have taken up the vaccine nanoparticles release into circulation
>>>> large numbers of exosomes containing spike protein along with critical microRNAs
- that induce a signaling response …. in recipient cells at distant sites.

The enrichment of GC content in vaccine mRNA will inevitably lead to an increase in the pG4 content of the vaccines. This, in turn, will lead to dysregulation of the G4-RNA-protein binding system
>>>> and a wide range of potential disease-associated cellular pathologies
>>> including suppression of innate immunity,
- neurodegeneration,
and malignant transformation

We also identify potential >>> profound disturbances in regulatory control…... of protein synthesis
>>> and cancer surveillance.

These disturbances potentially have >>>>> a causal link
- to neurodegenerative disease,
- myocarditis,
- immune thrombocytopenia,
- Bell's palsy,
- liver disease,
- impaired adaptive immunity,
- impaired DNA damage response
- and tumorigenesis.
We show evidence….. from the VAERS database …….supporting our hypothesis.

Mishra and Banerjea (2021) investigated the role of exosomes in the cellular response of SARS-CoV-2 spike-transfected cells. They wrote in the abstract:
“We propose that SARS-CoV-2 gene product, Spike, is able to modify the host exosomal cargo, which gets transported to distant uninfected tissues and organs

>>>> and can initiate a catastrophic …...immune cascade within Central Nervous System (CNS).”

We will connect these underlying physiological effects
- with both .... realized
- and yet-to-be-observed >>>> morbidities.

We anticipate that implementation >>>>> of booster vaccinations .. on a wide scale
>>> will amplify... all …. of these problems.

We believe …… a comprehensive risk/benefit assessment …… of the mRNA vaccines
>>> questions them …… as being ….. positive contributors to public health


I've got rheumatoid arthritis and fibromyalgia and I've had no help from social services.
donald t
Very disappointing about the government's decision on Evusheld as I am a shielder and I am unable to leave my house due to being immune compromised. I don't know when I will next be able to go on vacation. The government seems to have moved on from Covid and left us behind.
donald t
Dumped hik this am and reinvested here.
Hope I've got it right - but who knows! Not much good news about atm.

Adverse vaccine events in 5 to 11 year olds

Dr. John Campbell


Vaccines Are Destroying People’s Immunity Through ‘Immune Imprinting’: Dr. Robert Malone [Part 1]

Maybe so but keeping above 11,000 is a battle and now looks like a downward trend , under 10,000 looks probable
Why, I'm seeing strong institutional buying here, I'm following the crowd, momentum is up.
Personally I'd wait
Going to add here, I see Baillie Gifford have bought big here recently..
Deutsche Bank raises AstraZeneca price target to 12,000 (11,500) pence - 'buy'
ShoreCap stays at 'buy' on AstraZeneca, sees further upgrades ahead on product pipeline

Analysts at ShoreCap reiterated their 'buy' recommendation for shares of drugs giant AstraZeneca, describing its second quarter top-line growth of 37% year-on-year at constant exchange rates "impressive".

"AZN have delivered a strong second quarter, with Q2 benefitting from a full quarter of Alexion integration and several products beating consensus expectations," analyst Dr.Susie Jana said in a research note sent to clients.

"Oncology was in line overall due to strong commercial execution and lower COVID-19 related headwinds than anticipated."

The analyst also called attention to the fact that AstraZeneca was reinvesting its strong revenues into research and development.

And there was more yet to come.

"AZN has a strong mid to late-stage pipeline, we expect product and candidate related news flow in 2023 to lead to further upgrades. A strong set of results underpinning the long-term growth story," she added.

"AZN shares trade on a FY23F PER of 16.8x, a c 5% premium versus US and European peers (mean 16.1x), which we believe is warranted based on its industry-leading earnings growth and pipeline prospects."

Are they different to any other company if the truth be known?. A fantastic company with enormous growth potential.
singing the blues
AstraZeneca PLC on Friday reported a swing to second-quarter net loss after booking a large foreign-exchange charge in its accounts, but raised its full-year revenue guidance due to better-than-expected Covid-19 medicine revenue.

The Anglo-Swedish pharma giant said it now expects to report a low twenties percentage rise in total revenue for the year, up from previous guidance of high teens percentage. It also said revenue from Covid-19 medicines are expected to be flat compared with 2021. It had previously guided for a low-to-mid twenties percentage fall.

AstraZeneca posted a net loss of $372 million for the quarter compared with a profit of $1.19 billion for the same period a year earlier.

Revenue for the quarter rose to $10.77 billion, from $8.22 billion. Revenue consensus was $10.45 billion.

Core earnings per share--one of the company's preferred metrics--rose to $1.72 in the quarter, compared with $0.90 and a consensus of $1.57.

Consensus figures have been taken from FactSet and are based on 16 analysts' projections.

AstraZeneca reiterated that it expects core EPS growth in the mid-to-high twenties percentage.

The board has increased its interim dividend to $0.93 a share compared with $0.90 for the first half of 2021.

Write to Ian Walker at

(END) Dow Jones Newswires

July 29, 2022 02:54 ET (06:54 GMT)

Pascal Soriot, Chief Executive Officer, AstraZeneca, said:

"AstraZeneca had a strong financial first half of 2022, and great pipeline delivery. We announced practice-changing data for several medicines including Enhertu in breast cancer, Farxiga in heart failure and Ultomiris in neuromyelitis optica spectrum disorder.

We have made great progress in our efforts to combat COVID-19 . Vaxzevria is estimated to have saved more than six million lives during the first year of roll-out, and Evusheld has protected hundreds of thousands of immunocompromised people, enabling them to return to a more normal life. Evusheld continues to demonstrate activity against new variants.

Given the ongoing performance of our underlying business and the contribution of our COVID-19 medicines, we are updating our revenue guidance for 2022. This has enabled us to increase our R&D investment in the exciting number of pipeline opportunities that can benefit patients and drive long term sustainable growth for our company. We look forward to announcing the results of several important late-stage trials this year and next ".

Would you trust AZ to tell you the truth when they knowingly kept the fatal side effects of the covid jab hidden?
25 Jul '22 - 07:07 - 5614 of 5615
0 0 0

AstraZeneca PLC said Monday that Tezspire has been recommended for approval in the EU for the treatment of severe asthma.

The pharmaceutical giant said Tezspire has been recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Asthma is a disease that affects around 14 million people living in the European Union.

Write to Kyle Morris at

(END) Dow Jones Newswires

July 25, 2022 02:44 ET (06:44 GMT)

TOP NEWS: AstraZeneca breast cancer drug wins approval in EU

Tue, 19th Jul 2022 09:22
Alliance News

(Alliance News) - AstraZeneca PLC on Tuesday said a breast cancer

drug developed with Tokyo-based partner Daiichi Sankyo Co Ltd has been approved in the European Union.

The Cambridge, England-based pharmaceutical company's Enhertu is aimed at treating those with unresectable or metastatic HER2-positive breast cancer, who have received one or more prior anti-HER2-based regimens.

HER-2 is a growth promoting protein. Unresectable tumours cannot be removed with surgery, while metastatic refers to cancer that spreads from where it started to another part of the body.

In the DESTINY-Breast03 Phase III trial, Enhertu reduced the risk of disease progression or death by 72% compared to trastuzumab emtansine. Trastuzumab emtansine is a type of targeted cancer drug for early breast cancer or breast cancer that has spread or come back within six months of finishing treatment.


Executive Vice President Dave Fredrickson said: "With this approval, patients across Europe with HER2-positive metastatic breast cancer will have the opportunity to be treated with Enhertu even earlier in the treatment of their disease, improving their chance for better outcomes beyond what we can already offer patients treated in later-line settings."

More than 530,000 patients are diagnosed with breast cancer each year, and about one in five patients are considered HER2-positive.

Following the approval by the European Commision, AstraZeneca will pay USD75 million to Daiichi Sankyo as a "milestone payment in 2nd-line HER2-positive metastatic breast cancer," the company noted.

In March 2019, Daiichi Sankyo and AstraZeneca signed a deal to develop and commercialise Enhertu.

Shares were down 0.6% at 11,033.00 pence each on Tuesday morning in London. Sankyo shares closed 2.9% lower at JPY3,508 each in Tokyo.

By Xindi Wei;

grupo guitarlumber
AstraZeneca PLC said Tuesday that its Enhertu drug has been approved in the European Union for patients with HER2-positive metastatic breast cancer .

The pharmaceutical giant said that the results of the Destiny-Breast03 study showed that Enhertu reduced the risk of disease progression or death by 72% when compared with trastuzumab emtansine.

Enhertu is jointly developed and commercialized by Astrazeneca and Daiichi Sankyo Co., the company said.

Write to Sabela Ojea at; @sabelaojeaguix

(END) Dow Jones Newswires

July 19, 2022 02:27 ET (06:27 GMT)

grupo guitarlumber
Now where the F... is Buybadly!
Now where the F... is Buybadly!
Chat Pages: 233  232  231  230  229  228  227  226  225  224  223  222  Older
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221207 18:09:19